18 results about "Sedative effect" patented technology

The utility model discloses a snore-ceasing patch, which relates to the technical field of medical supplies and comprises a snore-ceasing patch body, a cutting groove is arranged at the top end of the snore-ceasing patch body, and an arc-shaped groove is arranged on one side of the cutting groove. A first plaster sheet is arranged at the top end of the snore stopping sheet body and fixedly connected to the top end of the snore stopping sheet body, a second plaster sheet is arranged at the bottom end of the snore stopping sheet body, and absorbent cotton is arranged on the inner side of the second plaster sheet. The first plaster sheet is arranged at the top end of the snore stopping sheet body, mild medicine is arranged on the inner side of the first plaster sheet, the sedation effect can be effectively improved after a patient inhales the medicine, the sleep quality is improved, the second plaster sheet is arranged at the bottom end of the snore stopping sheet body, the medicine cotton is arranged on the inner side of the second plaster sheet, and the snore stopping sheet is convenient to use. The refreshing agent is arranged in the pillow, so that the respiratory capacity in sleep can be effectively increased, the breathing quality is improved, and the sleep quality is effectively improved.

Compositions comprising at least 10% of a compound of formula (I) by weight, at least 10% of a compound of formula (II) by weight, or at least 10% by weight of a combination of a compound of formula (I) and a compound of formula (II), are disclosed herein. Methods for administering the compositions are disclosed herein. The methods can be used to produce a calming effect, produce an analgesic effect, manage pain, treat cough, treat anxiety, treat depression, treat opioid use disorder, and / or to treat opioid withdrawal in a subject.

The breathing system for a patient to inhale a substance from, the substance being for analgesic, anaesthetic and / or sedative effect on the patient, comprises a patient airway interface, an adding means 16, a user control 18 and a control means. The patient airway interface is mountable on the patient so that inhaling and exhaling occur through the patient airway interface consecutively and repetitively. The adding means is for adding the substance to gas to be inhaled, wherein the substance is provided in volatile liquid form, and vaporisation of the substance into the gas is facilitated. The user control is coupled to the control means to provide input thereto in response to operation of the user control. The user control can be mountable to the hand of a patient so that the patient can operate the user control in a user action, thereby to send information indicative of substance being wanted to the control means, and / or in response to stimulus.

The invention belongs to the technical field of medicines, and particularly relates to combined application of nicotine and theobromine in relieving bipolar affective disorder as well as a product and a preparation method of the product. The problems that traditional western medicines are large in curative effect fluctuation, have addiction risks, are obvious in side effects and the like are solved, the anti-anxiety characteristic of nicotine and the analgesic and sedative effects of theobromine are used for synergistically exerting a multi-dimensional intervention effect, and curative effect superposition is achieved. The invention also determines the ratio of nicotine to theobromine (the mass ratio of nicotine to theobromine is 1: 100-1000), provides a reliable basis for clinical application, and is beneficial to improving the treatment effect. According to the scheme, the technical blank that natural components are combined to be used for treating bipolar affective disorder is filled, a brand new path is provided for intervention of the disease, and important theoretical exploration value and practical application significance are achieved.

A preparation method of an external patch for preoperative sedation relates to the field of medical preparations containing organic effective components, and sequentially comprises the steps of preparing a main component pretreatment substance, preparing a matrix solution, preparing an ointment-containing paste and synthesizing the patch, the preparation method of the main component pretreatment substance comprises the following steps: preparing a mixed liquid by taking dexmedetomidine hydrochloride and floperidol as main components, carrying out spray granulation to obtain a composite solid dispersion, crushing the composite solid dispersion into powder, and mixing and stirring the powder with paraffin oil and superfine silica powder. In the patch prepared from dexmedetomidine hydrochloride and floperidol, the effective components can quickly penetrate through the skin mucous membrane, so that the effect of quickly taking effect is achieved, and a good sedative effect is achieved. The dispersion uniformity of main components in the patch is excellent, the RSD is within 2%, and the effect consistency of the patch is guaranteed. According to the dexmedetomidine hydrochloride tablet, the stability of dexmedetomidine hydrochloride is effectively improved, components are prevented from being decomposed in the long-term storage process, other impurities are not generated, and the shelf life is effectively prolonged to 24 months.

2-(2,5-dioxopyrrolidin-1-yl)propanamide and 2-(2-oxopyrrolidin-1-yl)propanamide derivatives with R-configuration at the stereogenic center are disclosed, showing broad-spectrum protective activity in animal models of epileptic seizures, pain, depression and anxiety that are simultaneously devoid of undesirable sedative effects. Additionally, the disclosed derivatives have neuroprotective effects in the in vitro and in vivo studies.

The invention relates to application of cannabidiol in preparation of a medicine for adjuvant therapy of hyperthyroidism, and belongs to the technical field of biological medicine. The invention aims to provide novel medical application of cannabidiol, namely application of cannabidiol in preparation of a medicine for adjuvant therapy of hyperthyroidism. Animal model in-vivo experiments prove that cannabidiol has a sedative effect on hyperthyroidism mice, can inhibit hyperactivity caused by hyperthyroidism and effectively relieve symptoms such as easy excitation, dysphoria and insomnia, is beneficial to emotion stabilization and creates favorable conditions for treatment of hyperthyroidism. Cell in-vitro experiments prove that cannabidiol can effectively block a stress signal channel triggered by corticosterone, relieve the stress reaction degree of liver cells, relieve the liver burden and promote liver function recovery, and a new intervention thought is provided for adjuvant therapy of hyperthyroidism liver injury.

The invention discloses a cinnabar nano-vesicle gel emplastrum with a tranquilizing and calming effect as well as a preparation method and application of the cinnabar nano-vesicle gel emplastrum. The method comprises the following steps: preparing target peptide modified cinnabar nano-vesicles by adopting a film dispersion method; dissolving cinnabar nano-vesicles in PBS as a phase C for later use; mixing the second framework material, the tackifier, the filler and the humectant to obtain a phase A; mixing a cross-linking agent, a cross-linking regulator, a penetration enhancer and a bacteriostatic agent to obtain a phase B; stirring and mixing the phase A, the phase B and the phase C, coating a non-woven fabric with the mixture, placing the non-woven fabric at room temperature, and covering the non-woven fabric with an anti-sticking film to obtain the target peptide modified cinnabar nano-vesicle gel emplastrum. The cinnabar nano-vesicle gel emplastrum can promote intestinal microorganisms to generate 5-hydroxytryptamine (5-HT), so that a cerebral cortex 5-HT1AR-cAMP pathway is activated, brain activity is adjusted, sleep conditions are improved, the cinnabar nano-vesicle gel emplastrum has slow release property, skin penetrability and intestinal tract targeting property, and the insecurity caused by direct oral administration of cinnabar into blood circulation is also solved.

To provide an adjustment device capable of adjusting a biological rhythm and a life rhythm of an object person.SOLUTION: An adjustment device (40) includes a spray device (41) that supplies a substance having an awakening effect or a sedative effect to an object space (S) in which an object (T) is present, and a control device (100). The control device (100) controls the spray operation of the spray device (41) based on a biological rhythm of an object (T) and reference data serving as a reference of the biological rhythm, or based on a life rhythm of the object (T) and reference data serving as a reference of the life rhythm.SELECTED DRAWING: Figure 3

The application discloses a benzodihydrofuran compound, a pharmaceutical composition thereof and application. The application provides a compound as shown in formula I or a pharmaceutically acceptable salt thereof. The compound has a sedative effect and helps to relieve the mania symptoms of patients with mental diseases.

This invention relates to a levotetrahydropalmatine citrate, its preparation method, and its applications, belonging to the field of pharmaceutical technology. This invention provides a levotetrahydropalmatine citrate. Studies have shown that compared to other salt forms, the citrate form of levotetrahydropalmatine significantly improves its solubility. Furthermore, research has confirmed that levotetrahydropalmatine citrate can significantly reduce drug relapse preferences, with efficacy comparable to or even better than the injectable form, without causing significant adverse reactions and exhibiting good safety. Simultaneously, the sedative effect of levotetrahydropalmatine citrate is far superior to other salt forms. In addition, levotetrahydropalmatine citrate has therapeutic effects on sleep disorders, effectively shortening sleep onset time, increasing sleep duration, and improving sleep quality. Therefore, the levotetrahydropalmatine citrate provided by this invention has broad application prospects in the preparation of drugs for sedation, analgesia, treatment of sleep disorders, and treatment of drug addiction.

The application discloses a potent non-sleepy antiemetic and anti-motion sickness pharmaceutical composition and application thereof, and belongs to the technical field of medicines.The composition comprises five active ingredients of pheniramine maleate, caffeine, vitamin B6, scopolamine and lidocaine.Through the synergistic effect of the components, the composition can strongly inhibit the dizziness and vomiting reaction caused by the vestibular stimulation, and meanwhile, the sedative effect of the antihistamine drug is antagonized by caffeine, so that the side effect of sleepiness of the traditional anti-motion sickness drug is avoided while the anti-motion effect is ensured.Experiments show that the effect of the composition in an anti-motion sickness animal model is obviously better than that of each single drug and a conventional positive control drug.The composition can be used for preparing various pharmaceutical preparations for preventing and treating motion sicknesses such as car sickness, ship sickness and aircraft sickness, and has important clinical application value.

The utility model provides a nasal cavity anesthesia dosing device which comprises a dose adjusting part, a spray injection part and a protective cap, the dose adjusting part comprises a first shell, a knob sleeve and a spiral push rod, and the required medicament dose is selected through the knob sleeve and the spiral push rod; accurate administration can be carried out according to dosage requirements of different patients; the spray injection part comprises a second shell, a liquid medicine core and a spray head, the interior of the second shell is hollow, a containing space for containing medicine is formed in the second shell, and before use, medical staff can detach the first shell from the second shell and place the liquid medicine core in the second shell to be fixed and replaced; the spiral push rod can extend into the second shell and abut against the liquid medicine core. The rotary knob sleeve is arranged at the tail of the dosage adjusting part and connected with the spiral push rod, the spiral push rod can push out liquid medicine in the liquid medicine core, and vaporific liquid medicine with the corresponding injection milliliter number is pushed out through the atomizing spray head to reach the surface of the mucous membrane of the nasal cavity, so that the anesthesia and sedation effects are achieved.

The present invention provides a pharmaceutical composition comprising a local anesthetic and fospropofol disodium, a preparation method and use thereof, and a combination drug, belonging to the field of pharmaceutical preparations. The pharmaceutical composition and the combination drug have both analgesic and sedative effects. Through the additive or synergistic effect between the drugs, the onset time of fospropofol disodium can be shortened, the pharmacodynamic effect can be enhanced, the drug dosage can be reduced, the pH value of the fospropofol disodium solution can be improved, adverse reactions during anesthesia induction can be alleviated, the number of medications required by anesthesiologists can be reduced, and the anesthesia induction process can be made more convenient, thereby achieving a more ideal anesthetic effect.

The application belongs to the technical field of biological medicine, and specifically discloses application of benserazide hydrochloride in preparation of anxiolytic drugs. The application first finds that benserazide hydrochloride plays an anxiolytic role by regulating the kynurenine metabolic pathway. Animal experiments prove that benserazide hydrochloride can promote the generation of kynurenine and its downstream metabolite 3-hydroxyanthranilic acid, and maintain the stable level of 3-hydroxykynurenine, thereby improving the function of the metabolic pathway and restoring the nervous system homeostasis. Behavioral experiments show that benserazide hydrochloride can increase the exploration behavior of zebrafish and reduce the avoidance behavior, and meanwhile, does not cause inhibition of motor function or sedative effect, and shows good safety and selectivity. The application provides a theoretical basis and a new drug source for the prevention and / or treatment of anxiety.

The application provides a new compound with local anesthesia and general deep sedation function and medical use. The new compound has the structure shown in the following formula: The compound has local anesthesia and also exhibits a unique general sedative effect, suggesting that it has general anesthesia potential, and its rapid onset and recovery characteristics make it possible to be used for developing a new intravenous anesthetic.

2-(2,5-dioxopyrrolidin-1-yl)propanamide and 2-(2-oxopyrrolidin-1-yl)propanamide derivatives with R-configuration at the stereogenic center are disclosed, showing broad-spectrum protective activity in animal models of epileptic seizures, pain, depression and anxiety that are simultaneously devoid of undesirable sedative effects. Additionally, the disclosed derivatives have neuroprotective effects in the in vitro and in vivo studies.